Gain Therapeutics Inc

GANXNASDAQ · USD
1.07USD-0.04 (-3.61%)
162

Gain Therapeutics Inc (GANX) Covered Calls

Gain Therapeutics Inc trades in the Biotechnology industry with an IV Rank of 99.60%, high versus the past year. GANX's highest covered call setup is the $1.00 strike expiring Nov 20, 2026, sorted by theoretical annualized return. It's 6.38% out of the money with 4 days to expiration, a 11.70% return until expiration, and a 1,067.82% theoretical annualized return. Across the setups shown, annualized returns run from 22.96% to 1,067.82% at strikes between $1.00 and $1.00, with 4 to 186 days to expiration, as of Nov 16, 2026.

Read more

Running GANX covered calls helps you generate income from Gain Therapeutics Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best GANX covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call pairs limited risk with a clear income profile. If GANX stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling GANX covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given GANX covered call is worth writing.

Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases.

2026-11-2041.006.380.050.5011.0011.701067.82-5.32+0.634700.45
2027-05-211861.006.380.050.7011.0011.7022.96-5.32+0.691,5000.65

As of Nov 16, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV Rank99.60% High
  • Market cap (M$)49
  • 52 weeks high-74.42%
  • 52 weeks low18.09%
  • Analyst recommendationStrong Buy
    1.00
  • Target price$6.60
    516.82% above the current stock price
  • Dividend—
  • Payout ratio—
  • Earnings date2026-11-10
  • P/E—
  • Future P/E—
  • EPS (ttm)-0.43
  • EPS growth next 5 years-2.92%

As of Nov 18, 2026